Tools
Stock profile

GLOBUS MEDICAL INC (GMED)

GMED · Latest close $70.53 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$70.53
As of Nov 18, 2026
Tracked funds holding
1 of 149
2026 Q2 13F filings
Opened / added
0 / 0
vs previous quarter
Trimmed / exited
1
vs previous quarter

GLOBUS MEDICAL INC (GMED) is held by 1 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $5.8M sold). 1 member of Congress reported 2 purchases vs 0 sales. Latest close $70.53 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 10, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-5.8M
Congress
2 buys vs 0 sales
Fundamentals
Revenue · FY2025
Red flags
screens flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Ruane Cunniff LP — 1 tracked fund hold GMED. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 4 sales ($5.8M). Insider trading 1 member of Congress reported buying (2 purchases vs 0 sales). Latest buy: Sep 3, 2026. Politician trading

Often held alongside

BECTON DICKINSON & CO (BDX) · BOSTON SCIENTIFIC CORP (BSX) · BAXTER INTERNATIONAL INC (BAX) · STRYKER CORP (SYK) · Solventum Corp (SOLV) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Ruane Cunniff LP0.01%6,008HELD Q3 filed Nov 16
Maverick Capital——EXITED

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: -7.9% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

96.8250.092024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding599 of 8,857 filers
Long-only filers among them595
Change vs 2026 Q1+6 net · 557 entered · 551 exited
Shares reported, all filers118,875,320
Reported value, all filers$9.1B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNYSE
IndustrySurgical & Medical Instruments & Apparatus (SIC 3841)
Revenue · FY2025$2.9B
Net income · FY2025$537.9M
Total assets · FY2025$5.3B
Shares outstanding134,261,914
Market cap (at latest close)$9.5B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Aug 4, 2026.

Short interest

Shares short · Oct 15, 20268,189,831
Share of shares outstanding6.10%
Days to cover5.47

Shares short at recent settlements — Jul 31, 2026: 6.9M · Aug 14, 2026: 6.8M · Aug 31, 2026: 6.6M · Sep 15, 2026: 6.8M · Sep 30, 2026: 8.4M · Oct 15, 2026: 8.2M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Aug 4, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20261,791
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 2026<0.1%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 2 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 2K.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Aug 4, 2026.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 4 sales by 2 insiders ($5.8M).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Nov 10, 2026TOBIN JAMES RSell37,662$75.10$2.8MSEC filing
Nov 10, 2026TOBIN JAMES RSell4,004$75.68$303.0KSEC filing
Nov 4, 2026RHOADS ANN DSell5,000$85.00$425.0KSEC filing
Sep 15, 2026TOBIN JAMES RSell30,000$74.58$2.2MSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Sep 15, 2026TOBIN JAMES RDirector30,000$2.2MSep 15, 2026SEC filing
Aug 18, 2026ZARRILLI STEPHEN TDirector25,000$2.2MAug 18, 2026SEC filing
Jun 5, 2026Davidar David DDirector25,000$2.0MJun 5, 2026SEC filing
Apr 14, 2026DeFord John AFormer Director30,000$2.8MApr 14, 2026SEC filing
Feb 25, 2026Huller KellyOfficer20,000$1.9MFeb 25, 2026SEC filing
Feb 12, 2026Huller KellyOfficer10,000$876.0KFeb 12, 2026SEC filing
Jan 8, 2026Kline KyleOfficer3,594$363.2KJan 8, 2026SEC filing
Jan 8, 2026Norwalk Leslie VDirector2,000$202.0KJan 8, 2026SEC filing
Dec 12, 2025Norwalk Leslie VDirector4,000$355.0KDec 12, 2025SEC filing
Dec 1, 2025Kline KyleOfficer18,542$1.7MDec 1, 2025SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Apr 30, 2026Vanguard Capital ManagementSC 13G5,885,5605.2%Mar 31, 2026SEC filing
Mar 26, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
May 14, 2025JANUS HENDERSON GROUP PLCSC 13G/A7,029,2946.1%Mar 31, 2025SEC filing
Apr 24, 2025BlackRock, Inc.SC 13G/A10,487,2379.1%Mar 31, 2025SEC filing
Feb 14, 2025JANUS HENDERSON GROUP PLCSC 13G/A6,614,8125.8%Dec 31, 2024SEC filing
Feb 5, 2025BlackRock, Inc.SC 13G/A10,636,6097.8%Dec 31, 2024SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

1 member of Congress reported buying (2 purchases vs 0 sales). Bought by Democrats. Latest buy: Sep 3, 2026.

Source: U.S. House Clerk and U.S. Senate eFD STOCK Act periodic transaction reports, as of Nov 16, 2026. Reported amounts are ranges, and reports can arrive up to 45 days after the trade.

Recent activity by member

MemberChamberPartyBuysSellsLatestAmount range
Cisneros, GilbertHouseD20Sep 3, 2026$15,001 - $50,000

Member-level activity in the current window, most recent first (House data to Nov 16, 2026, Senate to Oct 1, 2026). House reports arrive as PDFs without transaction-level rows in the current corpus, so this table shows per-member totals, not individual trades; the member page lists the underlying filings. Senate rows link the same way — the member page carries the eFD filing links.

Committee jurisdiction

Industry: Surgical & Medical Instruments & Apparatus (SIC 3841). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 77 Lobbying Disclosure Act filings named this company as client, 2008–2026; most common issues: Health Issues (54), Medicare/Medicaid (47), Taxation/Internal Revenue Code (19).

Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Politicians

· Bought by Members — Last 6 months: bought by a member of the U.S. Congress

Financial Screens

· Growth — Revenue up every year for 5 straight years

· Graham — Sound finances and a long run of profits

· Lynch PEG — Cheap against its growth rate

· Cash Flow (FCF) — Positive free cash flow in each of the last 3 years, with an FCF yield of at least 5%

· Neff Total Return Ratio — Growth plus dividends divided by P/E is high

· Earnings Quality (Cash Conversion) — Profits that actually come back as cash

Red Flags

· Earnings Manipulation Suspect (Beneish) — Beneish M-Score above -1.78

Key figures

· Growth — Latest revenue: $2.9B · 5-yr revenue CAGR: 30.1% · Straight growth years: 15

· Graham — Current ratio: 4.26 · Straight profitable years: 16 · Debt ratio: 0.16 · Latest net income: $537.9M

· Lynch PEG — P/E: 21.15 · 5-yr EPS growth: 31.2% · PEG: 0.68

· Cash Flow (FCF) — Latest FCF: $588.8M · FCF yield: 5.2% · Positive FCF years: 3

· Neff Total Return Ratio — EPS growth: 31.2% · Dividend yield: 0.0% · P/E: 21.15 · Neff ratio: 1.47

· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 2.81 · Operating cash flow: $753.4M · Net income: $537.9M

· Bought by Members — Members buying: 1 · Buy txns: 2 · Sell txns: 0 · Latest buy: Sep 3, 2026

· Earnings Manipulation Suspect (Beneish) — M-Score: -1.74 · Receivables index: 1.54 · Margin deterioration: 1.14 · Sales growth index: 1.53 · Accruals ratio: -2.4%

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Also held by the tracked funds that hold GMED — ranked by lift, the co-holding pattern described in Methodology: BECTON DICKINSON & CO (BDX) · BOSTON SCIENTIFIC CORP (BSX) · BAXTER INTERNATIONAL INC (BAX) · STRYKER CORP (SYK) · Solventum Corp (SOLV) · Medline Inc. (MDLN) · 3M CO (MMM) · WEST PHARMACEUTICAL SERVICES INC (WST).

8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.

Recent 8-K filings

FiledItemsSource
Nov 5, 20262.02 Results of Operations and Financial Condition · 8.01 Other Events · 9.01 Financial Statements and ExhibitsSEC filing
Aug 6, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Jun 4, 20265.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

BECTON DICKINSON & CO (BDX) · Track Record: how the signals scored · Practice timing on GMED

One email a week: the week’s new filings and research. Subscribe free

← GMAB  ·  GMTL →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.